Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
50
LSB Quote, Financials, Valuation and Earnings
Last price:
$3.19
Seasonality move
:
16.02%
Day range:
$2.60 - $3.50
52-week range:
$1.88 - $11.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.47x
P/B ratio:
0.66x
Volume:
124.9K
Avg. volume:
56.4K
1-year change:
-34.22%
Market cap:
$56.5M
Revenue:
$80.2M
EPS (TTM):
-$2.01
Analysts' Opinion
-
Consensus RatingLakeShore Biopharma has received a consensus rating of Buy. The company's average rating is a Buy based on 0 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of --, LakeShore Biopharma has an estimated upside of 964.57% from its current price of $2.96.
-
Price Target DownsideAccording to analysts, the lowest downside price target is -- representing 100% downside risk from its current price of $2.96.
Fair Value
-
According to the consensus of 0 analysts, LakeShore Biopharma has 964.57% upside to fair value with a price target of -- per share.
LSB vs. S&P 500
-
Over the past 5 trading days, LakeShore Biopharma has overperformed the S&P 500 by 21.04% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
LakeShore Biopharma does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
LakeShore Biopharma has grown year-over-year revenues for 0 quarters straight. In the most recent quarter LakeShore Biopharma reported revenues of --.
Earnings Growth
-
LakeShore Biopharma has grown year-over-year earnings for 0 quarters straight. In the most recent quarter LakeShore Biopharma reported earnings per share of --.
Enterprise value:
101.8M
EV / Invested capital:
0.74x
Price / LTM sales:
0.47x
EV / EBIT:
--
EV / Revenue:
1.15x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$71.2M
Return On Assets:
-3.11%
Net Income Margin (TTM):
-7.57%
Return On Equity:
-7.94%
Return On Invested Capital:
-15.63%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2022-09-30 | 2023-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $97.9M | $28.3M | $13.4M | |
| Gross Profit | -- | -- | $76.6M | $22.1M | $11M | |
| Operating Income | -- | -- | -$23M | $2.4M | -$13.8M | |
| EBITDA | -- | -- | -$21.8M | $2.4M | -$13.9M | |
| Diluted EPS | -- | -- | -$3.98 | -$0.46 | -$1.57 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $122.3M | $128.1M | $121.5M | |
| Total Assets | -- | -- | $217.3M | $220.8M | $204.3M | |
| Current Liabilities | -- | -- | $80.7M | $90.9M | $104.1M | |
| Total Liabilities | -- | -- | $350.7M | $144.5M | $118.4M | |
| Total Equity | -- | -- | -$133.4M | $76.4M | $85.9M | |
| Total Debt | -- | -- | $62.8M | $74.7M | $52.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2022-09-30 | 2023-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -$15.7M | -$20.2M | |
| Cash From Investing | -- | -- | -- | -$2.8M | -$3.2M | |
| Cash From Financing | -- | -- | -- | $7.6M | $6.2M | |
| Free Cash Flow | -- | -- | -- | -$18.5M | -$23.4M | |
LSB
Sector
Market Cap
$56.5M
$43.9M
Price % of 52-Week High
26.43%
45.73%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-34.22%
-29.11%
Beta (5-Year)
--
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$2.61
200-day SMA
Sell
Level
$5.63
Bollinger Bands (100)
Sell
Level
2.4 - 5.7
Chaikin Money Flow
Sell
Level
-20.8M
20-day SMA
Buy
Level
$2.73
Relative Strength Index (RSI14)
Buy
Level
55.32
ADX Line
Buy
Level
13.7
Williams %R
Neutral
Level
-38.599
50-day SMA
Buy
Level
$2.77
MACD (12, 26)
Sell
Level
-0.07
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Neutral
Level
80.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.9396)
Sell
CA Score
(Annual)
Level (-1.8782)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (3.0486)
Sell
Piotroski F Score
(Annual)
Level (3)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
LakeShore Biopharma Co Ltd is a biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer. It has developed a proprietary PIKA immunomodulating technology platform and a new generation of preventive and therapeutic biologics targeting Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other virus infections. The company operates in China, the United States, Singapore, and the Philippines.
Stock Forecast FAQ
In the current month, LSB has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The LSB average analyst price target in the past 3 months is --.
-
Where Will LakeShore Biopharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that LakeShore Biopharma share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About LakeShore Biopharma?
Analysts are divided on their view about LakeShore Biopharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that LakeShore Biopharma is a Sell and believe this share price will drop from its current level to --.
-
What Is LakeShore Biopharma's Price Target?
The price target for LakeShore Biopharma over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is LSB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for LakeShore Biopharma is a Buy. 0 of 0 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LSB?
You can purchase shares of LakeShore Biopharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase LakeShore Biopharma shares.
-
What Is The LakeShore Biopharma Share Price Today?
LakeShore Biopharma was last trading at $3.19 per share. This represents the most recent stock quote for LakeShore Biopharma. Yesterday, LakeShore Biopharma closed at $2.96 per share.
-
How To Buy LakeShore Biopharma Stock Online?
In order to purchase LakeShore Biopharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is down 0.51% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 7.38% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.32% over the past day.
